17:40 , Oct 19, 2018 |  BC Week In Review  |  Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
22:17 , Oct 16, 2018 |  BC Extra  |  Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed beyond...
20:10 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest inhibiting MAPK could help treat autism. In a mouse model of autism, subcutaneous injection with a tool compound MAPK inhibitor decreased numbers of cortical progenitor cells and behavioral deficits and...
17:13 , Jul 20, 2018 |  BC Week In Review  |  Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an upfront...
10:02 , Jul 18, 2018 |  BC Extra  |  Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an upfront...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; melanoma Mouse studies suggest combining Mekinist trametinib with MAPK and CRAF inhibitors could help treat BRAF-dependent lung cancer and melanoma. In six PDX mouse models of BRAF-dependent lung cancer and five of BRAF-dependent...
21:51 , Feb 10, 2017 |  BC Week In Review  |  Company News

Q BioMed, Oklahoma Medical Research Foundation, RGCB deal

Q BioMed partnered with the non-profit Oklahoma Medical Research Foundation and the Indian government-owned RGCB to develop uttroside B, a preclinical chemotherapeutic, and its derivatives to treat hepatocellular carcinoma (HCC). The biotech cited an animal...
14:13 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Skin cancer Mouse studies suggest dual inhibition of MAP2K1/MAP2K2 or MAPK1/MAPK3 could help treat PTEN hamartoma tumor syndrome (PHTS), a type of skin hyperplasia that can become malignant. In a mouse model of PHTS, dual...
07:00 , Oct 10, 2016 |  BioCentury  |  Emerging Company Profile

Pellino play

Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking...